QLT Announces Second Quarter Results for 2009
...ose of the study is to determine if Visudyne combined with Lucentis reduces retreatment
rates compared with Lucentis monotherapy, while maintaining similar vision ...aluated against Lucentis monotherapy. The overall results showed that fewer retreatment
visits were required with the combination therapies than with Lucentis mono...
Good news for some hard-to-treat hepatitis C patients
... dose of consensus interferon and ribavirin.
"This study shows that select patients who have failed to respond to prior therapy are candidates for retreatment
with consensus interferon and ribavirin," Bacon said.
QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R) combination therapy
...terval of at least four months duration after Month 2. Median time to first retreatment
after month 2 was extended by ~1 month in the combination group (month 6) v... VA, anatomical changes and safety at every monthly visit, and the need for retreatment
was assessed at monthly visits from Month 3 to Month 11. Re-treatment was b...
QLT announces positive results from the evaluation of Visudyne(R) combination therapy
...termine if Visudyne combined with Lucentis reduces retreatment
rates compared with Lucentis monotherapy, while ma...monotherapy. The overall results showed that fewer retreatment
visits were required with the combination therapie...oup demonstrated the best results, with the fewest retreatment
visits and mean VA improvement most similar to Luc...
New treatment option for patients with chronic hepatitis C
... respond to treatment with peg-IFN and RBV can be successfully retreated with daily CIFN and RBV," the authors conclude. "The greatest SVR rate during retreatment
in the present study was observed in F0-F3 patients who had a partial virologic response during their prior course of treatment."
Schering-Plough Reports Financial Results for 2009 First Quarter
... TEMODAL Capsules. (Announced March 5)
Received FDA approval for expanded labeling for PEGINTRON and REBETOL combination therapy allowing for retreatment
of chronic hepatitis C patients 3 years of age and older with compensated liver disease who have failed prior therapy. (Announced March 11)
Physicians Coalition for Injectable Safety Says There are No Substitutes for Cosmetic Injections, Offers Solutions
...Nonanimal-Stabilized Hyaluronic Acid 100,000 Gel Particles/mL Filler on Two retreatment
Schedules: Results up to 18 months on Two retreatment
Schedules. Narins et. al. Dermatologic Surgery 2008;34:S2-S8.
(4) U.S. FDA...
Rituximab maintenance therapy improves survival in patients with relapsed follicular lymphoma
...were available for 985 patients.
Rituximab maintenance therapy was associated with a 40% improvement in overall survival relative to observation or retreatment
with rituximab at relapse. The improvement in overall survival was statistically significant for patients with relapsed or refractory lymphoma, but no...
QLT announces interim results of radical study evaluating Visudyne combination therapy
...udy is to determine if combination therapy reduces retreatment
rates compared with Lucentis monotherapy while mai...etters; Group 4: 4.4 letters). Although cumulative retreatment
rates were lower in all combination groups compare...follow up is needed to better compare the elective retreatment
rates in each group.
"Determining if Visudyne ...
Estrogen pills can benefit women with metastatic breast cancer
...n dependent tumors and the cycle starts over."
Ellis plans to continue to follow metastatic breast cancer patients to quantify the response rate to retreatment
with aromatase inhibitors when estrogen therapy stops working.
retreatment in Medical Technology
Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
...nal control. Of these, 454 patients were from the retreatment
study portion of the EPIC3 program and 172 were di...ng characteristics are less likely to benefit from retreatment
after failing a course of therapy: previous nonres....
Patients receiving PEGINTRON and REBETOL as retreatment
after failing a previous interferon combination re...
Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
...Patients with the following characteristics are less likely to benefit from retreatment
after failing a course of therapy: previous nonresponse, previous pegylated...th inhibition were common.
Patients receiving PEGINTRON and REBETOL as retreatment
after failing a previous interferon combination regimen reported adverse re...
FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
...ve patients. Patients less likely to benefit from retreatment
after failing a course of therapy include those wi...ine those patient groups most likely to respond to retreatment
as well as those unlikely to respond. Overall, pr...cians can identify which patients may be right for retreatment
with PEGINTRON combination therapy and may have th...
Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
...r-blinded study that assessed the safety and effectiveness of two different retreatment
schedules, 4.5 months or 9 months, after initial treatment of nasolabial fo...
Correction with Restylane (R) lasted for 18 months, regardless of retreatment
At 18 months, patients still had a 1.7 grade improvement i...
Genmab Announces Upcoming Ofatumumab Studies
... Front Line CLL, NHL and CLL retreatment
and Japanese Development Studies ...tment of front line CLL.
Phase II CLL ofatumumab retreatment
and maintenance treatment study
This study will examine the retreatment
and maintenance treatment of
refractory CLL patien...
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
...Data Presentations at DDW
Results from the EPIC3 Program: Platelet Counts Are Strong Predictors
of Sustained Viral Response (SVR) in the retreatment
Interferon/Ribavirin Non-Responders (NR). Poynard, T. et al. Poster S1000,
Abstract No. 442673, Sunday, May 18, 8:00 a.m. - 5:00 p.m., Sai...
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
...tained viral response (SVR) is dependent on baseline characteristics
in the retreatment
of previous alfa interferon/ribavirin (I/R)
nonresponders (NR): final resul... combination with
ribavirin in initial therapy, the optimal approach to the retreatment
patients with chronic HCV for whom initial treatment was not effective, ...
New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
...ill be presented from 23 studies of VELCADE based therapies for
the treatment of relapsed MM. These data, including settings where VELCADE
is used for retreatment
and in patients with renal impairment, support the
importance of adding VELCADE in combination with numerous emerging and
Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
...ent. Ongoing patient evaluations showed
maintenance of ACR responses with repeated single doses of TRU-015 at
six-month intervals through at least two retreatment
courses. Total serum
IgG levels remained within normal limits. In addition, subjects treated
with three or more courses of therapy experienced persist...
Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
...r of the SPIRIT III clinical trial. "In SPIRIT III, the risk for
patients on the important clinical endpoint of MACE -- cardiac death, heart
attack or retreatment
in the diseased artery area -- was approximately 43
percent lower with XIENCE V than TAXUS at 1 year. A reduction in MACE with
Xience V compared to TA...
retreatment in Medical Products
Seibel II IntraLase Flap Lifter & Retreatment Spatula, Titanium
Description: Unique In-Line Footplates Are Turned 90 Degrees To Allow Full Visualization Of The Diamond Blade While Incising Tissue.
Special Mirror-Polished Double Footplate Construction Insures Precise Blade Depth Penetration.
Pre-Set Blade Extension Settings Of 0.5mm, 0.55mm, 0.6mm, Including Ful...
Company:Rhein Medical, Inc.
LASIK Retreatment Forceps
Description: LASIK Retreatment
Forceps - Also available in Titanium...
Company:Khosla Medical & Surgical, Inc.
Rousseau IntraLASIK Flap Spreader
Description:...e With The Smooth Lifting Of The Flap.
Designed To Be Used Specifically For Lamellar Flaps Created With The IntraLase TMFS Laser System, And For retreatment
Flaps Originally Created By Mechanical Microkeratomes. Optimal Results Are Experienced With Flaps Measuring 100+ Microns....
Company:Rhein Medical, Inc.
Probst Lasik Spatula
Description:... Lasik spatula useful for protecting a previous flap for retreatment
to lift and smooth the corneal flap....
Company:Bausch & Lomb Storz
retreatment in Biological News
Gene therapy may protect normal tissues during radiation retreatment for lung cancer
The ice ages made massive changes to the Earth's landscape
The ice ages made massive changes to the Earth's landscape. But what was happening below the ice in the oceans?
Research by marine scientists reveals that it was a time of mass destruction as whole communities of animals were wiped out...
JCI table of contents: Aug. 16, 2007
...linical Investigation, Charles Sawyers and colleagues show that 2 of 12 patients whose cancer had returned after treatment with dasatinib responded to retreatment
with imatinib. Analysis of the BCR-ABL proteins from these patients revealed that their BCR-ABL had only the dasatinib-resistance mutation. By contras...
Novel therapy combinations gain ground in treating hepatitis
...akthroughs and relief for these patients."
Valopicitabine (NM283), Alone or with Peg-Interferon, Compared to Peg Interferon/Ribavirin (pegIFN/RBV) retreatment
in Hepatitis C Patients with Prior Non-Response to PegIFN/RBV: Week 24 Results [Abstract 4]
More than half of currently treated hepatitis patients...
retreatment in Biological Technology